Glass House Brands (GLAS) Cash from Investing Activities (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Cash from Investing Activities of -$2.7 million for Q1 2026, up 58.98% year-over-year from -$1.7 million in Q1 2025, and down 26.08% quarter-over-quarter from -$2.2 million in Q4 2025.
Glass House Brands (GLAS) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Cash from Investing Activities for 7 consecutive years, with -$2.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 58.98% year-over-year to -$2.7 million; the TTM figure through Mar 2026 stood at -$23.8 million (down 63.14% YoY), while the FY2025 annual figure was -$27.7 million, down 169.5% from the prior year.
- Cash from Investing Activities eased to -$2.7 million in Q1 2026 per GLAS's latest filing, from -$2.2 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $13.0 million in Q1 2022 and bottomed at -$12976.5 billion in Q4 2022.
- Historically, Cash from Investing Activities has averaged -$1143.1 billion across 5 years, with a median of -$2.4 million in 2024.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 2198.29% — and 2023, when it tumbled 19738531056.36%.
- Glass House Brands' Cash from Investing Activities stood at -$12976.5 billion in 2022, then soared by 100.0% to $6.3 million in 2023, then slumped by 140.91% to -$2.6 million in 2024, then increased by 14.92% to -$2.2 million in 2025, then fell by 26.08% to -$2.7 million in 2026.
- Business Quant data shows GLAS's Cash from Investing Activities at -$2.7 million in Q1 2026, -$2.2 million in Q4 2025, and -$9.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Glass House Brands | 837.25 Mn | 818.69 Mn | 15.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.75 Mn |
| Mar 31, 2026 | -2.75 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Sep 30, 2025 | -9.60 Mn |
| Sep 30, 2025 | -9.60 Mn |
| Jun 30, 2025 | -9.27 Mn |
| Jun 30, 2025 | -9.27 Mn |
| Mar 31, 2025 | -6.70 Mn |
| Mar 31, 2025 | -6.70 Mn |
| Dec 31, 2024 | -2.56 Mn |
| Dec 31, 2024 | -2.56 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Jun 30, 2024 | -3.91 Mn |
| Jun 30, 2024 | -3.91 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Dec 31, 2023 | 6.26 Mn |
| Dec 31, 2023 | 6.26 Mn |